GlassScriptPhysician profile
Neethi Paranji
NPI 1568814333
$541.44
in general payments reported to CMS, 2019-2025
11 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.92 · 2023: $168 · 2024: $160 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $125.78 | 2022-2025 | |
| Becton, Dickinson and Company | $71.12 | 2025 | Hemosphere |
| Phathom Pharmaceuticals, INC. | $67.76 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $61.97 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $49.25 | 2023 | Stelara, Simponi, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.23 | 2022-2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $34.72 | 2024 | Dupixent |
| Celgene Corporation | $29.34 | 2023 | |
| Braintree Laboratories, INC. | $23.90 | 2023 | Suflave |
| Boston Scientific Corporation | $18.21 | 2024 | |
| Ferring Pharmaceuticals INC. | $16.16 | 2024 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neethi Paranji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.